Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
International Journal of Stroke (IJS) shared a reminding post on X:
”Poor outcome at 3-months is frequent in acute stroke patients with P1 and P2 occlusion.”
Read the full article here.
Flashbacks on stroke management in the ‘Predictors of poor outcome in acute stroke patients with posterior cerebral artery occlusion and medical management‘ article by Candice Sabben et al.
A kind reminder, do not miss recanalization!
In patients with acute ischemic stroke due to isolated proximal posterior cerebral artery (PCA) occlusion, poor 3-month functional outcomes remain frequent under medical management alone.
This cohort study highlights that over half of patients treated without reperfusion therapies experienced unfavorable outcomes.
Clinical and radiological predictors of poor recovery were identified, underscoring the need for optimized treatment strategies.
Greater use of intravenous thrombolysis (IVT) and future therapies focused on improving recanalization and minimizing hemorrhagic transformation warrant investigation in prospective trials.
Your daily updates on stroke management featured in Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia